by Stefan Ravello | Oct 9, 2026 | Oncology
As the treatment landscape for relapsed extensive-stage small-cell lung cancer (ES-SCLC) rapidly evolves, clinicians are faced with an expanding array of biomarker-directed therapies, novel therapeutic targets, and emerging clinical data that are reshaping treatment...
by Stefan Ravello | Sep 23, 2026 | Multiple Sclerosis, Neurology
The landscape of multiple sclerosis (MS) management is rapidly evolving, requiring community-based neurology clinicians to navigate complex paradigms, from the central role of B-cells in disease progression to the subtle emergence of progression independent of relapse...
by Stefan Ravello | Aug 31, 2026 | mCRPC, Oncology, Prostate Cancer
Prostate cancer remains one of the most significant oncologic challenges in the United States, with an estimated 322,000 new cases projected in 2026 and approximately 3.4 million men currently living with the disease. Despite initial responses to androgen deprivation...
by Stefan Ravello | Jul 20, 2026 | Uncategorized
Advances in biomarker and genetic testing have transformed cancer care, creating new opportunities to personalize treatment and improve outcomes for patients with lung, colorectal, and prostate cancers. As testing recommendations, molecular targets, and treatment...
by Stefan Ravello | Jun 11, 2026 | Hematology-Oncology, Multiple Myeloma
As the treatment landscape for multiple myeloma evolves, emerging Cereblon E3 ligase modulators (CELMoDs) are poised to redefine how clinicians approach relapsed/refractory disease. This course examines how iberdomide and mezigdomide differ from traditional IMiDs...
